Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 15 May 2013 | By Louise Zornoza •
China's Food and Drug Administration (CFDA) last week issued instructions to Chinese provinces regarding the requirements for certifying active pharmaceutical ingredient manufacturers for the right to export their products to the European Union (EU) as of 2 July 2013.
Editor's Note: A previous iteration of this article said that the ingredients in question were excipients. They are in fact APIs. We regret the error.
The announcement, made on 7 May 2013 and issued with accompanying forms, requires provincial food and drug supervision and management departments to identify officials familiar with pharmaceutical good manufacturing practice (GMP) supervision and with a basic command of English by 20 May 2013. These officials will oversee the local export certification process, CFDA said.
If a company has not already obtained a production license for bulk drugs, its facilities must undergo and pass a GMP on-site inspection as well as meet the additional certification requirements. If a site does not comply with the current GMP requirements or does not comply with the conditions for certification, local authorities must inform CFDA within 24 hours so that the information can be forwarded to the EU.
By Louise Zornoza, RegLink News
Read all Breaking News from RegLink
Tags: Export, Excipient, EU